CLINICAL_TRIALS ClinicalTrials.gov record update

A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03373019
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:43.677818+00:00
Published At: 2017-12-14T00:00:00+00:00
Record Updated At: 2017-12-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Chidamide", "Lymphoma, B-Cell", "Lymphoma, Large B-Cell, Diffuse", "Neoplasm by Histology", "Neoplasms", "Lymphoproliferative Disorders", "Lymphatic Diseases", "Immunoproliferative Disorders", "Immune System Diseases", "Lymphoma, Non-Hodgkin", "Cyclophosphamide", "Rituximab", "Gemcitabine", "Cisplatin", "Dexamethasone", "HDAC Inhibitor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-12-14"
protocolSection.identificationModule.nctId: "NCT03373019"
protocolSection.identificationModule.officialTitle: "A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.